Accelerate global drug development: Leveraging China regulatory changes
China's pharmaceutical regulatory environment continues to evolve rapidly, creating both opportunities and challenges for global companies. Our recent webinar provided essential insights into these changes and practical strategies for success.
What You'll Learn
Our expert-led session covered:
- Streamlined Approval Pathways: How China's reformed Clinical Trial Application process is reducing development timelines and creating new opportunities for global sponsors
- Strategic Use of Foreign Data: Practical approaches for meeting NMPA requirements when leveraging global clinical data in Chinese submissions
- Breakthrough Therapy Strategies: Evidence-based guidance on qualifying for expedited review pathways, illustrated through Parexel-supported case studies
- Therapeutic Area Focus: Specialized regulatory considerations for rare disease and oncology products, with comparative analysis of Chinese and US frameworks
Understanding China's unique regulatory framework is essential for pharmaceutical companies looking to access one of the world's most significant and rapidly growing pharmaceutical markets. Our webinar provides the strategic insights needed to navigate this complex landscape efficiently and accelerate your global development programs.
Related Insights
Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025
Blog
The EU-CTR transition: Four key ways to prepare now
Jan 12, 2024
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Related Insights
Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025
Blog
The EU-CTR transition: Four key ways to prepare now
Jan 12, 2024
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Article
The technologies that are reshaping biotherapeutics manufacturing, an EU perspective
Jul 6, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Whitepaper
Optimizing the Route to Regulatory Approval for a Novel Vaccine
Aug 18, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023